ZVRA (Zevra Therapeutics) Treasury Stock: $-11.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZVRA Zevra Therapeutics Inc ZVRA
69 GF Score
Price $11.18
GF Value $20.92
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Zevra Therapeutics Treasury Stock?

Zevra Therapeutics ZVRA -2.27% 69 Treasury Stock is $-11.0 Mil as of Jun. 2026. GuruFocus rates ZVRA with a GF Score™ of 69/100 and a GF Value™ of $20.92 (Possible Value Trap). The stock has 5 warning signs investors should review.

Treasury stock is the portion of shares that a company keeps in their own treasury. Zevra Therapeutics's treasury stock for the quarter that ended in Jun. 2026 was $-11.0 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Zevra Therapeutics Treasury Stock Historical Data

* Premium members only.

The historical data trend for Zevra Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zevra Therapeutics Treasury Stock Chart

Zevra Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Treasury Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.81 -7.54 -10.98 -10.98 -10.98

Zevra Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.98 -10.98 -10.98 -10.98 -10.98
ZVRA
69GF Score
Zevra Therapeutics Inc ZVRA
Treasury Stock is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zevra Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Frequently Asked Questions Learn more about Treasury Stock →
What does a Treasury Stock of $-11.0 Mil mean?
Zevra Therapeutics (ZVRA) has a Treasury Stock of $-11.0 Mil as of Jun. 2026. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Zevra Therapeutics and its competitors.
Is Zevra Therapeutics' Treasury Stock too high?
Zevra Therapeutics' current Treasury Stock is $-11.0 Mil. Overall, Zevra Therapeutics has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zevra Therapeutics' Treasury Stock compare to TECX and RLMD?
Zevra Therapeutics' Treasury Stock of $-11.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Treasury Stock for a Biotechnology company?
A good Treasury Stock depends on the Biotechnology industry context. However, Treasury Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Treasury Stock mean?
A high Treasury Stock can signal that a stock is expensive relative to its fundamentals. Treasury stock is a contra-equity item that records the amount of stock not issued to shareholders. View historical data for Zevra Therapeutics and its competitors. Zevra Therapeutics's current Treasury Stock is $-11.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zevra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zevra Therapeutics (ZVRA) is currently considered Possible Value Trap. The stock's GF Value™ is $20.92, compared to a current price of $11.18 — trading 46.6% below its estimated fair value. The current Treasury Stock is $-11.0 Mil. Zevra Therapeutics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Treasury Stock calculated?
Treasury Stock is calculated from a company's financial statements. For Zevra Therapeutics (ZVRA), the current Treasury Stock is $-11.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zevra Therapeutics (ZVRA) Overvalued in 2026?

Based on GuruFocus' analysis, Zevra Therapeutics stock appears to be undervalued. The current stock price of $11.18 is trading 46.6% below its estimated GF Value™ of $20.92. GuruFocus considers Zevra Therapeutics to be Possible Value Trap.

Key valuation signals for ZVRA:

  • Treasury Stock: $-11.0 Mil
  • GF Value™: $20.92 vs. price of $11.18 (46.6% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the ZVRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zevra Therapeutics Business Description

Other Exchanges 1GDA:Germany
Address 101 Federal Street, Boston, MA, USA, 02110
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
69GF Score

Get the complete analysis for ZVRA

Treasury Stock is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.18
Price
$20.92
GF Value